|Bid||238.21 x 800|
|Ask||242.24 x 800|
|Day's Range||238.58 - 243.11|
|52 Week Range||177.05 - 264.97|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||19.66|
|Earnings Date||Oct. 22, 2020 - Oct. 26, 2020|
|Forward Dividend & Yield||6.40 (2.65%)|
|Ex-Dividend Date||Aug. 14, 2020|
|1y Target Est||262.76|
Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.
As the world awaits a COVID-19 vaccine, the next big advance in battling the pandemic could come from a class of biotech therapies widely used against cancer and other disorders - antibodies designed specifically to attack this new virus. Development of monoclonal antibodies to target the virus has been endorsed by leading scientists. Anthony Fauci, the top U.S. infectious diseases expert, called them "almost a sure bet" against COVID-19.
The COVID-19 pandemic is an "all hands on deck moment," David Reese, Amgen's research and development chief told Reuters. "We wanted a trial to be able to quickly sift through multiple agents and prioritize." The study is a collaboration among pharmaceutical industry members of the recently-formed COVID Research & Development Alliance, Quantum Leap Healthcare Collaborative, a partnership of medical researchers and investors, and the Food and Drug Administration.